HomeCompareAMAM vs JEPI

AMAM vs JEPI: Dividend Comparison 2026

AMAM yields 7.14% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMAM wins by $3.1K in total portfolio value
10 years
AMAM
AMAM
● Live price
7.14%
Share price
$28.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.1K
Annual income
$1,124.05
Full AMAM calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — AMAM vs JEPI

📍 AMAM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMAMJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMAM + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMAM pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMAM
Annual income on $10K today (after 15% tax)
$607.14/yr
After 10yr DRIP, annual income (after tax)
$955.44/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, JEPI beats the other by $343.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMAM + JEPI for your $10,000?

AMAM: 50%JEPI: 50%
100% JEPI50/50100% AMAM
Portfolio after 10yr
$30.5K
Annual income
$1,326.34/yr
Blended yield
4.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMAM right now

AMAM
Analyst Ratings
2
Buy
4
Hold
Consensus: Hold
Altman Z
34.9
Piotroski
2/9
JEPI
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMAM buys
0
JEPI buys
0
No recent congressional trades found for AMAM or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMAMJEPI
Forward yield7.14%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$32.1K$29.0K
Annual income after 10y$1,124.05$1,528.62
Total dividends collected$9.2K$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AMAM vs JEPI ($10,000, DRIP)

YearAMAM PortfolioAMAM Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$11,414$714.29$11,260$840.19+$154.00AMAM
2$12,975$761.97$12,641$907.94+$334.00AMAM
3$14,693$809.51$14,150$978.20+$543.00AMAM
4$16,578$856.71$15,795$1,050.85+$783.00AMAM
5$18,642$903.39$17,584$1,125.74+$1.1KAMAM
6$20,896$949.40$19,526$1,202.74+$1.4KAMAM
7$23,354$994.59$21,628$1,281.69+$1.7KAMAM
8$26,027$1,038.83$23,898$1,362.43+$2.1KAMAM
9$28,931$1,082.01$26,347$1,444.79+$2.6KAMAM
10$32,081$1,124.05$28,982$1,528.62+$3.1KAMAM

AMAM vs JEPI: Complete Analysis 2026

AMAMStock

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Full AMAM Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this AMAM vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMAM vs SCHDAMAM vs OAMAM vs KOAMAM vs MAINAMAM vs JEPQAMAM vs XYLDAMAM vs DIVOAMAM vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.